Sight-restoring chip targets human trials

Elon Musk’s brain chip firm Neuralink has announced the US Food and Drug Administration (FDA) approved human trials to begin on potentially sight-restoring technology.  

The brain implant aimed to assist mobility and visual restoration by connecting the brain with a computer interface that it said could restore autonomy to those with unmet medical needs. 

Neuralink said FDA approval was an important first step that could one day allow its technology to help many people. 

Recruitment for the clinical trials will open following further announcements, said Neuralink. This follows the rejection of an initial application for approval made early last year due to safety concerns.